In the Swedish Heart Failure Registry, HFmrEF resembled HFrEF rather than HFpEF with respect to IHD as underlying cause, and IHD was a poor prognostic factor in all these 3 HF subtypes.
Based on the results of the LEADER trial, GLP-1 analogue liraglutide is approved by the FDA to treat patients with type 2 diabetes.
In the BIOSTAT-CHF study, reaching less than 50% of the ESC guideline recommended dose of ACE-inhibitor/ARB or beta-blocker doses was associated with worse survival in HF patients.
Treatment with anacetrapib, in addition to atorvastatin, reduced major coronary events in patients at risk for cardiac events in the REVEAL study.
Short-acting statins are significantly more effective in lowering LDL-C and total cholesterol when taken in the evening, but long-acting statins are equally effective when taken in the morning and evening.
Prof. Stephen Nicholls indicates that because of the very different therapeutic approaches with respect to HDL, therapies still move forward, despite agents failing to demonstrate benefit. The HDL mimetic CER-001, on top of a statin, showed no effect on plaque regression in post-ACS patients.
In elderly patients on aspirin-based antiplatelet therapy without routine proton-pump inhibitor use, the long-term risk of disabling or fatal GI bleeding is 10 time higher, compared with younger age groups.
Anti-PCSK9 vaccination (AT04A) lowers LDL-c, atherosclerosis and inflammatory markers in mouse model for atherosclerosis. Phase I study into this vaccine has started
The phase III CANTOS study shows ACZ885 (canakinumab), in addition to standard care, reduces CV events in people with prior myocardial infarction and inflammatory atherosclerosis.
In a population-based cohort, the cumulative burden of BP, serum total- and LDL-C, and smoking from childhood and adolescence, were independently associated with worse midlife cognitive performance.
In AF patients with a single non-gender-related stroke risk factor, the risk of any bleeding was lower for apixaban and dabigatran compared with warfarin, while no difference in stroke prevention was seen.
In a case-control study on HeFH patients treated with potent statins, the addition of a PCSK9 antibody resulted in a greater decrease of tendon xanthomas thickness after 3 years of treatment.